Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
By Maggie Fick and Ahmed Aboulenein
LONDON/WASHINGTON, July 12 (Reuters) -Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
Novo Nordisk NOVOb.CO will meet withthe aides for Senators Jeanne Shaheen, Raphael Warnock, and Elizabeth Warren. In April, the lawmakerswrote to the company expressing alarm at its decision, announced in November, that it would permanently discontinue Levemir by the end of 2024.
Novo said it has given patients enough time to switch to other options, according to a May letter seen by Reuters. The company is unaware of plans for drug manufacturers to produce a biosimilar version of the insulin, the letter said, adding Novowould not assert any patent against such a version.
The sources declined to be named citing the sensitivity of the matter.
It was not clear who from Novo would attend the meeting. A company spokesperson denied there was a meeting scheduled. Shaheen, Warnock, and Warren's offices did not respond to a request for comment. Meetings between Congressional aides and company representatives are routine.
The Novo spokesperson said in a statement to Reuters on Friday that Levemir was not discontinued due to "success" of the company's newer medicinesWegovy and Ozempic, widely prescribed for weight loss and part of a new class of drugs called GLP-1 agonists.
When announcing in November the discontinuation of Levemir in the U.S.,Novo Nordisk cited manufacturing constraints, reduced patient access and available alternatives -- including its other long-acting insulin Tresiba.
The company said a number of long-acting insulins remainedon the market, but experts say it can be inconvenient and stressful for people with diabetes to change insulin regimens
Novo hasacknowledged during investor calls at quarterly earnings in the past yearthat it faces manufacturing capacity limitations for some products as it races to increase production of Wegovy and Ozempic.
The company along with rivals Eli Lilly LLY.N and Sanofi SASY.PA make 100% of all insulin sold in the U.S.
Last year all three companies agreed to cut U.S. list prices for insulin products by up to 75% in 2024, responding to political pressure to make the life-sustaining diabetes treatments more affordable.
Scrutiny of Novo has increasedat a time of record profits thanks to commercial success of Wegovy, launched in the U.S. in 2021. Sales of that weight-lossinjection propelled the company to the position of Europe's most valuable company worth 587 billion euros ($640 billion).
CEO Lars Jorgensen will testify before the Senate Committee on Health, Education, Labor and Pensions (HELP) in September on the high U.S. costs of Wegovy and Novo's diabetes drug Ozempic.
On Wednesday, Senator Bernie Sanders told Reuters he was confident that Novo can be convinced to cut prices after he publicly shamed the company over how its U.S. prices far surpass those charged in other countries.
Levemir's U.S. sales were 1.27 billion Danish crowns ($185.6 million) in 2023. Sales of Novo's other long-acting insulin Tresiba were 1.33 billion crowns last year.
($1 = 0.9172 euros)
($1 = 6.8419 Danish crowns)
Reporting by Maggie Fick in London and Ahmed Aboulenein in Washington; Editing by David Gregorio
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
